Skip to main content
Global Bioenergies logo

Global Bioenergies — Investor Relations & Filings

Ticker · ALGBE ISIN · FR0011052257 LEI · 969500H46XRAMTMVB676 PA Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2017-05-18 Capital/Financing Update
Country FR France
Listing PA ALGBE

About Global Bioenergies

https://www.global-bioenergies.com/?lan…

Global Bioenergies develops and commercializes a process to convert renewable resources, such as plant-based sugars and agricultural waste, into isobutene. The company's proprietary technology utilizes fermentation and synthetic biology to produce this key hydrocarbon, which serves as a platform molecule for various applications. The bio-isobutene can be converted into ingredients for the cosmetics industry, specialty chemicals, and renewable fuels. A primary strategic focus is the production of Sustainable Aviation Fuel (SAF) to support the decarbonization of the aviation sector. The process provides a bio-based alternative to petroleum-derived hydrocarbons, aiming to reduce CO2 emissions and dependence on fossil fuels.

Recent filings

Filing Released Lang Actions
GLOBAL BIOENERGIES COMMUNIQUE DE PRESSE
Capital/Financing Update Classification · 99% confidence The document text explicitly discusses the signing of a new contract for issuing convertible bonds with warrants (OCABSA) totaling 24 million euros, replacing a previous agreement. It details the structure of the financing (OCA and BSA), the objectives of the operation (securing financing until end of 2018), the dilution impact, and the legal modalities of the issuance. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing agreement itself.
2017-05-18 French
GLOBAL BIOENERGIES PRESS RELEASE
Capital/Financing Update Classification · 98% confidence The document is a press release dated May 18, 2017, announcing a significant financial transaction: the signing of a new debt issue agreement (convertible bonds and warrants, referred to as OCABSAs) with Bracknor Investment to replace a previous agreement. It details the structure, objectives, potential dilution, and legal framework of this financing arrangement. This content directly relates to fundraising, capital structure changes, and debt issuance, which aligns perfectly with the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER) as it focuses on a specific financing event rather than comprehensive periodic financial results. It is too detailed and specific to be a general Regulatory Filing (RNS) or a Report Publication Announcement (RPA).
2017-05-18 English
GLOBAL BIOENERGIES PRESS RELEASE
Regulatory Filings Classification · 95% confidence The document is a press release dated May 9, 2017, announcing that Global Bioenergies, Clariant, and INEOS received a significant EU funding package (€9.8 million) for a project (OPTISOCHEM) to demonstrate converting agricultural residues (wheat straw) into isobutene derivatives. This announcement details a specific business development, funding acquisition, and R&D cooperation, rather than releasing periodic financial results (ER/IR), providing audited financials (AR), or announcing management changes (MANG). It is a general corporate announcement regarding a strategic partnership and funding, which fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event announcement that doesn't fit the more specific categories like CAP (financing activity) or LTR (legal). Given the nature of the announcement—a major project funding and partnership update—it is a significant regulatory/corporate disclosure, but RNS is the most appropriate general category for non-standard, material announcements.
2017-05-09 English
GLOBAL BIOENERGIES COMMUNIQUE DE PRESSE
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 9, 2017, announcing that Global Bioenergies, Clariant, and INEOS received significant European funding (€9.8M total) for a project to demonstrate the production of isobutene derivatives from straw. The text details the project scope, partners, funding source (BBI-JU under HORIZON 2020), and includes quotes from management. This is a specific announcement regarding a research and development project and associated financing/collaboration, not a standard periodic financial report (like 10-K or IR) or a general regulatory filing (RNS). It best fits the 'Capital/Financing Update' category (CAP) because the core news is the securing of major funding for a strategic project, or potentially 'Regulatory Filings' (RNS) as a general announcement, but 'CAP' is more specific to the content focus on financing/grants for development. Given the focus on securing a large grant for a strategic R&D initiative, 'CAP' is the most appropriate fit over the general 'RNS'. The document length is substantial (6551 chars), indicating it is the full announcement, not just a brief notice of publication.
2017-05-09 French
GLOBAL BIOENERGIES COMMUNIQUE DE PRESSE
Report Publication Announcement Classification · 98% confidence The document is titled "GLOBAL BIOENERGIES : PUBLICATION DU DOCUMENT DE REFERENCE" (Publication of the Reference Document). The text explicitly states that Global Bioenergies announces the publication of its reference document as of December 31, 2016, which integrates the annual financial report, and that it has been filed with the AMF (Autorité des Marchés Financiers). Since the document itself is a short announcement stating that the main report (Document de Référence/Annual Report) has been published and is available elsewhere, it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. It is not the full 10-K or AR itself.
2017-04-27 French
GLOBAL BIOENERGIES COMMUNIQUE DE PRESSE
Regulatory Filings Classification · 95% confidence The document is a press release dated April 24, 2017, announcing a technical success: the production of bio-isobutene at the Leuna demonstrator scale. It details operational progress, future steps (increasing productivity, transferring lab strains), and regulatory approval (TÜV certification for the purification unit). This content is a specific operational update and announcement, not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a management discussion (MDA). Since it is a specific announcement about operational progress and technical milestones, and it doesn't fit the definitions for M&A (TAR), Capital changes (CAP), or Director dealings (DIRS), the most appropriate general category for a specific, non-financial results announcement that isn't covered elsewhere is Regulatory Filings (RNS), as it serves as a general regulatory/corporate update. However, given the highly specific nature of the definitions, this document is essentially a corporate update announcing progress on a key technology/project. It is not a standard Earnings Release (ER) which focuses on financial metrics, nor is it a Management Discussion (MDA). It is a specific operational announcement. Since there is no 'Operational Update' category, and it is not a formal financial report, RNS (Regulatory Filings / miscellaneous announcement) is the best fit among the provided options, as it is a general press release about company activity.
2017-04-24 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.